Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/28/2026, 12:00:00 AM
Presentation of positive late-breaking Phase 2 AMETHYST study data for litifilimab in cutaneous lupus erythematosus (CLE) at the 2026 American Academy of Dermatology Annual Meeting on 2026-03-28; medium importance is estimated as Phase 2 data for a breakthrough therapy typically results in ≥5% price movement, scheduled.
Korean Translation
2026-03-28로 예정된 2026년 미국피부과학회(AAD) 연례회의에서 피부 홍반성 루푸스(CLE) 츘료제 리티필리맙에 대한 긍정적인 후기 임상 2상 AMETHYST 연구 데이터 발표이며, 획기적 츘료제의 임상 데이터 발표는 통상 5% 이상의 주가 변동을 야기하므로 중간 중요도로 예정됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Exelixis Inc (EXEL) · Earnings Release
Exelixis is expected to report its Q1 2026 earnings on or around May 12, 2026, and analysts forecast EPS of approximately $0.73-$0.76; high importance reflects potential volatility from earnings surprises, forecasted and scheduled.
5/12/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol Myers Squibb Q1 2026 results conference call is scheduled for 2026-04-30; as the next earnings catalyst following the strong Q4 2025 outlook, a multi-percent share move is reasonably expected based on typical earnings volatility scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its financial results for the first quarter of 2026 before the market opens on April 29, 2026, followed by a conference call with management; a 5% price impact is estimated for this earnings release, scheduled.
4/29/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM